Thibaut du Fayet, Pherecydes CEO
Biotech consolidation continues as Nasdaq-listed Erytech merges with phage therapy developer
Just shy of two decades, the name of Erytech Pharma — and its mission of using red blood cells to deliver drugs for rare cancers and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
